KPC PharmaceuticalsInc Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.9yrs

Recente managementupdates

Recent updates

CEO

KPC PharmaceuticalsInc heeft geen CEO, of we hebben geen gegevens over hen.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ting Guo	Director	1.8yrs	geen gegevens	geen gegevens
Hui Zhou	Director	1.1yrs	geen gegevens	geen gegevens
Huawei Qiu	Chairman	1.8yrs	geen gegevens	geen gegevens
Jin Guo Xin	Independent Director	2.9yrs	CN¥100.00k	geen gegevens
Ke Liu	Independent Director	6yrs	CN¥100.00k	geen gegevens
Zheng Liang	Director	1.8yrs	geen gegevens	geen gegevens
Li Lin Xi	Employee Supervisor	6yrs	geen gegevens	geen gegevens
Zhang Weng Sen	Employee Supervisor	6yrs	geen gegevens	geen gegevens
Hongshen Li	Vice Chairman	less than a year	geen gegevens	geen gegevens
Zhi Yang	Independent Director	2.9yrs	CN¥100.00k	geen gegevens
Kang Deng	Supervisor	3.6yrs	geen gegevens	geen gegevens

2.9yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 600422 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.

KPC PharmaceuticalsInc Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.22 in 3Q 2023)

KPC Pharmaceuticals,Inc. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 20%

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

Dividend increased to CN¥0.20

KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.51 in FY 2022)

KPC Pharmaceuticals,Inc to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

KPC Pharmaceuticals,Inc to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.67 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.26 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.12 in 1Q 2020)

New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million.

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.60 in FY 2019)

New 90-day low: CN¥8.34

KPC Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥8.38

New 90-day low: CN¥9.12

New 90-day low: CN¥9.54

Third quarter earnings released

KPC Pharmaceuticals, Inc. to Report Q3, 2020 Results on Oct 22, 2020

A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million.

KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd.

First half earnings released

KPC Pharmaceuticals, Inc. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd